Drug Profile
BEA
Alternative Names: BEA protease inhibitorLatest Information Update: 23 Apr 2003
Price :
$50
*
At a glance
- Originator Medivir AB
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 29 May 2001 This compound is still in active development
- 02 Dec 1997 New profile
- 02 Dec 1997 Preclinical development for HIV-1 infections in Sweden (Unknown route)